Biomarin Short Long Term Debt vs Net Debt Analysis
BMRN Stock | USD 75.07 0.59 0.79% |
Biomarin Pharmaceutical financial indicator trend analysis is way more than just evaluating Biomarin Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biomarin Pharmaceutical is a good investment. Please check the relationship between Biomarin Pharmaceutical Short Long Term Debt and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
Short Long Term Debt vs Net Debt
Short Long Term Debt vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biomarin Pharmaceutical Short Long Term Debt account and Net Debt. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Biomarin Pharmaceutical's Short Long Term Debt and Net Debt is -0.44. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Net Debt in the same time period over historical financial statements of Biomarin Pharmaceutical, assuming nothing else is changed. The correlation between historical values of Biomarin Pharmaceutical's Short Long Term Debt and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Biomarin Pharmaceutical are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Short Long Term Debt i.e., Biomarin Pharmaceutical's Short Long Term Debt and Net Debt go up and down completely randomly.
Correlation Coefficient | -0.44 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Short Long Term Debt
The total of a company’s short-term and long-term borrowings.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Biomarin Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's Tax Provision is very stable compared to the past year. As of the 3rd of June 2024, Enterprise Value Over EBITDA is likely to grow to 74.10, while Selling General Administrative is likely to drop about 246.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.4B | 1.6B | 1.8B | 1.9B | Total Revenue | 1.8B | 2.1B | 2.4B | 2.5B |
Biomarin Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
Biomarin Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biomarin Pharmaceutical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.7B | 5.8B | 6.0B | 6.4B | 6.8B | 7.2B | |
Short Long Term Debt Total | 848.1M | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B | |
Other Current Liab | (13.0M) | 289.2M | 329.4M | 346.6M | 354.2M | 372.0M | |
Total Current Liabilities | 932.5M | 492.5M | 539.8M | 588.9M | 1.2B | 1.2B | |
Total Stockholder Equity | 3.1B | 4.1B | 4.3B | 4.6B | 5.0B | 5.2B | |
Property Plant And Equipment Net | 1.0B | 1.0B | 1.0B | 1.1B | 1.1B | 1.2B | |
Net Debt | 410.7M | 426.0M | 491.8M | 358.5M | 378.7M | 216.1M | |
Retained Earnings | (1.7B) | (861.6M) | (925.7M) | (789.2M) | (621.6M) | (652.6M) | |
Accounts Payable | 570.6M | 191.4M | 193.0M | 231.2M | 315.5M | 331.3M | |
Cash | 437.4M | 649.2M | 587.3M | 724.5M | 755.1M | 792.9M | |
Non Current Assets Total | 2.7B | 3.5B | 3.7B | 3.6B | 3.9B | 4.1B | |
Non Currrent Assets Other | 122.0M | 142.2M | 151.8M | 176.2M | 121.2M | 72.7M | |
Cash And Short Term Investments | 753.8M | 1.1B | 1.0B | 1.3B | 1.1B | 595.1M | |
Net Receivables | 377.4M | 448.4M | 373.4M | 461.3M | 633.7M | 665.4M | |
Common Stock Shares Outstanding | 179.0M | 191.7M | 182.9M | 189.0M | 191.6M | 127.6M | |
Liabilities And Stockholders Equity | 4.7B | 5.8B | 6.0B | 6.4B | 6.8B | 7.2B | |
Non Current Liabilities Total | 635.2M | 1.2B | 1.2B | 1.2B | 713.0M | 586.6M | |
Inventory | 680.3M | 698.5M | 776.7M | 894.1M | 1.1B | 1.2B | |
Other Current Assets | 130.7M | 129.9M | 110.4M | 104.5M | 141.4M | 148.5M | |
Other Stockholder Equity | 4.8B | 5.0B | 5.2B | 5.4B | 5.6B | 5.9B | |
Total Liab | 1.6B | 1.7B | 1.7B | 1.8B | 1.9B | 2.0B | |
Property Plant And Equipment Gross | 1.0B | 1.0B | 1.8B | 1.9B | 1.9B | 2.0B | |
Total Current Assets | 1.9B | 2.3B | 2.3B | 2.8B | 3.0B | 3.1B | |
Accumulated Other Comprehensive Income | 20.2M | (16.1M) | 14.4M | (3.9M) | (38.6M) | (36.7M) | |
Intangible Assets | 456.6M | 417.3M | 388.7M | 338.6M | 294.7M | 244.4M | |
Common Stock Total Equity | 178K | 180K | 182K | 184K | 211.6K | 126.8K | |
Short Term Investments | 316.4M | 416.2M | 426.6M | 567.0M | 318.7M | 276.3M | |
Common Stock | 180K | 182K | 184K | 186K | 189K | 133.2K | |
Other Assets | 612.0M | 1.6B | 1.6B | 1.6B | 1.8B | 1.9B | |
Long Term Debt | 486.2M | 1.1B | 1.1B | 1.1B | 593.1M | 553.3M | |
Property Plant Equipment | 1.0B | 1.0B | 1.0B | 1.1B | 1.3B | 1.3B | |
Other Liab | 98.1M | 174.3M | 113.7M | 73.5M | 84.5M | 81.8M | |
Net Tangible Assets | 2.5B | 3.5B | 3.7B | 4.1B | 4.7B | 4.9B | |
Retained Earnings Total Equity | (1.7B) | (1.7B) | (861.6M) | (925.7M) | (833.1M) | (874.8M) | |
Long Term Debt Total | 830.4M | 486.2M | 1.1B | 1.1B | 1.2B | 730.7M | |
Capital Surpluse | 4.7B | 4.8B | 5.0B | 5.2B | 6.0B | 3.7B | |
Long Term Investments | 412.0M | 285.5M | 507.8M | 333.8M | 611.1M | 353.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.722 | Earnings Share 1.06 | Revenue Per Share 13.12 | Quarterly Revenue Growth 0.088 | Return On Assets 0.0177 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.